Have Xbiotech insiders bought shares recently?

Yes. Insiders of Xbiotech (XBIT) filed 2 open-market purchases in the last 90 days; the latest was filed on Nov 13, 2026.

How often do Xbiotech insiders buy and sell shares?

Since 2015, Xbiotech insiders reported 25 open-market purchases and 64 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.

Who is selling Xbiotech stock?

No open-market sale by an insider of Xbiotech (XBIT) was filed with the SEC in the last 90 days.

Do members of Congress trade XBIT?

No trade in Xbiotech (XBIT) was disclosed by a member of Congress in the last 12 months.

When does Xbiotech report its next results?

Xbiotech's next results are expected on Mar 11, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Xbiotech (XBIT) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at XBIT buy and sell in the last 90 days?Which members of Congress and which funds traded XBIT recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

XBIT price and disclosed activity

−26.0% (−$0.69) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Show the 2 trades in this range as a list

John Simard, Director · Insider purchase, about $143Ktraded Nov 3, 2026, filed Nov 13, 2026
John Simard, Director · Insider purchase, about $711Ktraded Oct 26, 2026, filed Oct 28, 2026

Insider open-market trades, filed in the last 90 days2 buys · 0 sales~$855K boughtInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, last 12 monthsNoneNo followed fund reported a changeFund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Austin, Tx.

Last 12 months

−26.0%

S&P 500 +12.3% over the same dates

Market value

$59.8M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 315K shares sold short (1.0% of shares outstanding), +4.8% vs the previous count, 2.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

The last year in context

Trading desk

Against the S&P 500 over the year

XBIT −29.2%S&P 500 fund (SPY) +10.4%

Since Nov 12, 2025, XBIT is down 29.2% and the index fund is up 10.4%: 40 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.

How much XBIT moves

A usual day: ±1.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14): 5.6%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall: −8.1%Nov 19, 2025
Largest one-day rise: +11.6%Dec 3, 2025
Deepest fall of the year: −33.2%From the close of Nov 12, 2025 to Oct 26, 2026.
Days of 5% or more: 13Out of 252 sessions, in either direction.

End-of-day prices. These figures describe the past year and say nothing about what comes next.

On the public record for Xbiotech over the 12 months to Nov 14, 2026: 2 clinical trials.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

−$40.8M

This quarter −$4.51M, a year earlier −$6.04M

Net debt

—

Debt —, cash $110M, at Jun 30, 2026

Net income, last 12 months

−$45.1M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 29, 2015.

Insider buying and selling since 2015

Insiders of Xbiotech reported 25 open-market purchases and 64 sales since 2015; purchases in 4 different years, most recently 2026.

Year	Bought	Sold
2026	$855K2×2 trades	—
2021	—	$5.64M20×20 trades
2020	—	$44.7M12×12 trades
2019	$11.4M9×9 trades	$71K2×2 trades
2018	$313K8×8 trades	$2.28M21×21 trades
2016	$300K6×6 trades	$300K2×2 trades
2015	—	$439K7×7 trades

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

When insiders usually buy

Last results

Jul 29, 2015

More than 30 days ago

Next results, expected

Mar 11, 2027

Purchases after results

Not enough history

From Xbiotech's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Xbiotech's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Red flags in its filings

Oct 26
Top officer leaving
“Shivaswamy was named interim CEO following the retirement of Founder John Simard.”
8-K on sec.gov
Dec 9
Top officer leaving
“(“XBiotech” or the “Company”) announces that John Simard notified members of the Board of Directors beginning on December 5, 2025 of his intent to retire from his role as President and Chief Executive Officer of the Company, effective as of December 8, 2025.”
8-K on sec.gov

From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.

Late-stage clinical trials

0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in rheumatoid arthritis, axial spondyloarthritis. The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Insider buying

John SimardDirector

Filed yesterday

Bought

~$143K70K sh @ $2.05

Traded Nov 3 · filed 10 days later

Since the trade −1.5% · S&P 500 0.0% · to Nov 13

A Xbiotech director paid $143K out of pocket for Xbiotech shares.

Want the short version?

Xbiotech

How this filing works

Questions about Xbiotech insider trading

Insiders who traded Xbiotech

Other Pharmaceutical Preparations companies

XBIT price and disclosed activity

The last year in context

Latest results: quarter ending Jun 30, 2026

Insider buying and selling since 2015

When insiders usually buy

Red flags in its filings

Late-stage clinical trials

Latest

~$143K70K sh @ $2.05

~$711K369K sh @ $1.93

Late-stage clinical trials

Insider buying and selling since 2015

When insiders usually buy

The last year in context

Red flags in its filings